The purpose of this prospective study is to analyze function and phenotype of blood neutrophils in cystic fibrosis patients and the impact of Pseudomonas aeruginosa chronic infection, treatment with CFTR modulators and acute exacerbation on blood neutrophils phenotype and function.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
47
4 tubes of 7 ml per sample (a single sample)
4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment
Cochin hospital, AP-HP
Paris, France
Quantification of blood low density neutrophils in cystic fibrosis (CF)
Quantitative flow cytometric evaluation of neutrophil membrane markers that differ according to whether they are : * mature neutrophils : CD16high, CD15high, CD33high, CD10high * or Low density neutrophils (LDG) : CD16low, CD15neg, CD33 neg, CD10 neg. Comparison of neutrophil membrane markers profile in CF patients versus control blood-donors.
Time frame: Through study completion, an average of 1 year
Transcriptomic analysis of blood neutrophils in cystic fibrosis (CF)
Transcriptomic analysis of blood neutrophil proinflammatory or immunomodulatory potential. Comparison of transcriptomic blood neutrophil profile in CF patients versus control blood-donors.
Time frame: Through study completion, an average of 1 year
Effector function analysis of blood neutrophils in CF.
Comparison of effector function analysis of blood neutrophils of CF patients versus control blood-donors.
Time frame: Through study completion, an average of 1 year
Phagocytosis potential of blood neutrophils in CF.
Comparison of phagocytosis potential of blood neutrophils of CF patients versus control blood-donors.
Time frame: Through study completion, an average of 1 year
Survival/apoptosis balance analysis in CF
Survival / apoptosis balance analysis : (PCNA localization) in CF patients blood neutrophils versus control blood-donors.
Time frame: Through study completion, an average of 1 year
Quantification of blood low density neutrophils in CF vs other chronic inflammatory disorders.
Quantitative flow cytometric evaluation of neutrophil membrane markers that differ according to whether they are: * mature neutrophils : CD16high, CD15high, CD33high, CD10high * Low density neutrophils (LDG) : CD16low, CD15neg, CD33 neg, CD10 neg. Comparison of neutrophil membrane markers profile in CF patients versus patients with other chronic inflammatory disease (eg. Rheumatoid arthritis, inflammatory bowel disease).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Through study completion, an average of 1 year
Quantification of blood low density neutrophils in CF according to different clinical situations.
Quantitative flow cytometric evaluation of neutrophil membrane markers. * At stable state: * presence or absence of airway chronic infection with PA * whether or not patients are treated Ivacaftor-Lumacaftor * At beginning of exacerbation or after antibiotic treatment. * Before or after Ivacaftor-Tezacaftor-Elexacaftor treatment
Time frame: Through study completion, an average of 1 year
Transcriptomic analysis of blood neutrophils in CF according to different clinical situations.
Transcriptomic analysis of blood neutrophil proinflammatory or immunomodulatory potential. * At stable state: * presence or absence of airway chronic infection with PA * whether or not patients are treated Ivacaftor-Lumacaftor * At beginning of exacerbation or after antibiotic treatment. * Before or after Ivacaftor-Tezacaftor-Elexacaftor treatment
Time frame: Through study completion, an average of 1 year
Effector function analysis of blood neutrophils in CF according to different clinical situations.
Effector function analysis of blood neutrophils: * At stable state: * presence or absence of airway chronic infection with PA * whether or not patients are treated Ivacaftor-Lumacaftor * At beginning of exacerbation or after antibiotic treatment. * Before or after Ivacaftor-Tezacaftor-Elexacaftor treatment
Time frame: Through study completion, an average of 1 year
Phagocytosis potential of blood neutrophils in CF according to different clinical situations.
Phagocytosis potential analysis of blood neutrophils in CF: * At stable state: * presence or absence of airway chronic infection with PA * whether or not patients are treated Ivacaftor-Lumacaftor * At beginning of exacerbation or after antibiotic treatment. * Before or after Ivacaftor-Tezacaftor-Elexacaftor treatment
Time frame: Through study completion, an average of 1 year
Survival/apoptosis balance analysis in CF according to different clinical situations.
Survival / apoptosis balance analysis (PCNA localization): * At stable state: * presence or absence of airway chronic infection with PA * whether or not patients are treated Ivacaftor-Lumacaftor * At beginning of exacerbation or after antibiotic treatment. * Before or after Ivacaftor-Tezacaftor-Elexacaftor treatment.
Time frame: Through study completion, an average of 1 year